<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573609</url>
  </required_header>
  <id_info>
    <org_study_id>0001</org_study_id>
    <nct_id>NCT03573609</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness and Safety of Supratube Device</brief_title>
  <acronym>SUPRANAV</acronym>
  <official_title>Multicenter, Controlled, Randomized Clinical Trial to Evaluate the Effectiveness and Safety of the New Supratube Invention Device to Prevent Pneumonia Associated With Mechanical Ventilation: &quot; Supra-nav Project &quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Cardiovascular de Colombia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Cardiovascular de Colombia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the trial:

      Trial design: Two-parallel arm, double-blind, individually randomized controlled trial.

      Primary endpoint:

      Clinical evaluation of sinus, oropharyngeal, tracheal, bronchial or pulmonary infections
      during orotracheal intubation and hospital admission.

      Secondary endpoints:

      Volume of oropharyngeal secretions aspirated per unit of time (for 24 hours) by the SupraTube
      and Complications during the use of the SupraTube device: erosions, lacerations, Bleeding,
      displacement, migration, need for withdrawal.

      Inclusion criteria:

        -  Adult patient

        -  Orotracheal intubation ≤ 72 hours

        -  Hospitalized in ICU

        -  integrity of upper airways

      Exclusion criteria:

        -  International patients

        -  Coagulopathic patients

        -  oncology patients

        -  patients with maxillofacial surgery

        -  Absence of close responsible family member

        -  Tracheostomy, shock, local or systemic non-controlled infection

      Trial treatment:

      Intervention:

      Aspiration of secretions with the supranav device

      Control:

      Usual respiratory care

      Expected sample size, enrollment and expected number of centers:

      Sample size = 108

      Recruitment start date:

      Recruitment end date:

      Follow-up end date:

      Number of centers: 2

      Statistical considerations:

        -  Intention to treat analysis

        -  The primary outcomes will be analyzed using
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Anticipated">January 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator associated events</measure>
    <time_frame>24 hours after extubation</time_frame>
    <description>A group of all the conditions that result in a significant and sustained deterioration in oxygenation, defined as a greater than 20% increase in the daily minimum fraction of inspired oxygen or an increase of at least 3 cm H2O in the daily minimum positive end-expiratory pressure (PEEP) to maintain oxygenation. It is imperative to understand that both infectious conditions (such as tracheitis, tracheobronchitis, and pneumonia) and noninfectious conditions (such as atelectasis, pulmonary embolism, pulmonary edema, ventilator-induced lung injury, and others) may fulfill this VAE definition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 hours after extubation</time_frame>
    <description>Number of patientes with Bleeding and lacerations in the oropharynx</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Intensive Critical Unit</condition>
  <condition>Pneumonia</condition>
  <condition>Aspiration</condition>
  <condition>Prevention and Control</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual respiratory care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supranav</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory care with &quot;supranav&quot; which is a continuous supraglottic suction device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supranav</intervention_name>
    <description>Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation</description>
    <arm_group_label>Supranav</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intubated adult patients with mechanical ventilation.

          -  To have a closest responsible relative

          -  Integrity of the airways

        Exclusion Criteria:

          -  Need of orofacial, cervical or respiratory tract surgical procedures

          -  Patients with tracheostomy

          -  Shock,

          -  Local or systemic uncontrolled infection

          -  Blood dyscrasia, neoplastic diseases

          -  Physiological alteration

          -  Acute or chronic decompensated pathology that is not controlled at the time of
             selection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alba L Ramirez Sarmiento, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Cardiovascular de Colombia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana I Cáceres Rivera, PhD</last_name>
    <phone>+576394040</phone>
    <phone_ext>1*056</phone_ext>
    <email>dianacaceresrivera@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alba L Ramirez Sarmiento, PhD</last_name>
    <phone>+576394040</phone>
    <phone_ext>1*056</phone_ext>
    <email>alba.ramirez.sarmiento@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundación Cardiovascular de Colombia</name>
      <address>
        <city>Piedecuesta</city>
        <state>Santander</state>
        <zip>681011</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana I Cáceres Rivera, PhD</last_name>
      <phone>+576394040</phone>
      <phone_ext>1*056</phone_ext>
      <email>dianacaceresrivera@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alba L Ramirez Sarmiento, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauricio A Orozo Levi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilo E Pizarro Gómez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana I Cáceres Rivera, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Rey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos F Reyes Martinez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anderson Bermon Angarita, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

